Patents by Inventor Lankenau Institute For Medical Research

Lankenau Institute For Medical Research has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130231264
    Abstract: Synergy occurs when combined agents induce a response greater than the sum of their individual effects. The present invention provides new high throughput screening methods to detect agents acting synergistically in orthogonally pooled mixtures. Computational de-convolution of the pooled data with software reveals single-actives in the pools with twice the statistical power and with much greater efficiency than common high throughput screening approaches. Cross-correlating the orthogonal data reveals pools with activity that cannot be ascribed to any single compound. The components of such ‘Orphan’ activity pools are then tested individually and in all possible combination-pairs to identify and confirm synergy.
    Type: Application
    Filed: March 21, 2013
    Publication date: September 5, 2013
    Inventor: Lankenau Institute for Medical Research Chemical Genomics Center
  • Publication number: 20130227719
    Abstract: The nucleotide and amino acid sequences of indoleamine 2,3-dioxygenase-2 (IDO2) and methods of use thereof are provided.
    Type: Application
    Filed: March 5, 2013
    Publication date: August 29, 2013
    Applicant: LANKENAU INSTITUTE FOR MEDICAL RESEARCH
    Inventor: Lankenau Institute for Medical Research
  • Publication number: 20130183388
    Abstract: Novel indoleamine 2,3-dioxygenase (IDO) inhibitors, compositions comprising the same, and methods of use thereof are disclosed.
    Type: Application
    Filed: February 26, 2013
    Publication date: July 18, 2013
    Applicant: LANKENAU INSTITUTE FOR MEDICAL RESEARCH
    Inventor: Lankenau Institute for Medical Research
  • Publication number: 20130164328
    Abstract: This disclosure demonstrates a novel therapy immunological approach using polyamine-based therapy (PBT) for relieving tumor-induced suppression of the patient's immune system. The demonstration of the pharmacological release from the naturally occurring polyamine-mediated immune suppression offers profound impact on the immunotherapy of cancer together with a variety of diseases caused by the disease-causing vector's ability to evade an immune reaction. This therapeutic approach is equally applicable to disease states whereby immune system suppression by polyamines has been demonstrated including; bacterial infections, parasitic infections including malaria and typanosomiasis, viral infections, peptic ulcers and gastric cancer due to H. Pylori infection together with prevention of pregnancy. With a small molecule drug, used in combination with DFMO, the pharmacological manipulation of polyamine levels for therapeutic benefit in various disease states is possible.
    Type: Application
    Filed: February 20, 2013
    Publication date: June 27, 2013
    Applicants: Lankenau Institute For Medical Research, Aminex Therapeutics
    Inventors: Aminex Therapeutics, Lankenau Institute For Medical Research